| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurosurgery | 24 | 2023 | 682 | 3.980 |
Why?
|
| Neuroma, Acoustic | 23 | 2023 | 455 | 2.790 |
Why?
|
| Neurosurgical Procedures | 31 | 2024 | 2076 | 2.520 |
Why?
|
| Meningioma | 26 | 2024 | 1220 | 2.470 |
Why?
|
| Brain Neoplasms | 60 | 2024 | 9118 | 2.160 |
Why?
|
| Meningeal Neoplasms | 20 | 2024 | 1253 | 2.030 |
Why?
|
| Craniotomy | 18 | 2016 | 736 | 1.830 |
Why?
|
| Craniopharyngioma | 9 | 2023 | 279 | 1.710 |
Why?
|
| Neurofibromatosis 2 | 10 | 2023 | 388 | 1.390 |
Why?
|
| Pituitary Neoplasms | 11 | 2023 | 1322 | 1.310 |
Why?
|
| Intracranial Aneurysm | 11 | 2011 | 1271 | 1.240 |
Why?
|
| Radiosurgery | 16 | 2022 | 1330 | 1.120 |
Why?
|
| Decompression, Surgical | 11 | 2024 | 603 | 0.970 |
Why?
|
| Laminectomy | 4 | 2021 | 226 | 0.910 |
Why?
|
| Trigeminal Neuralgia | 6 | 2007 | 103 | 0.900 |
Why?
|
| Aneurysm, Ruptured | 6 | 2011 | 455 | 0.870 |
Why?
|
| Glioblastoma | 18 | 2024 | 3464 | 0.820 |
Why?
|
| Cranial Irradiation | 9 | 2022 | 393 | 0.790 |
Why?
|
| Spinal Stenosis | 5 | 2016 | 259 | 0.790 |
Why?
|
| Hospital Mortality | 16 | 2012 | 5349 | 0.790 |
Why?
|
| Spondylolisthesis | 4 | 2016 | 173 | 0.740 |
Why?
|
| Postoperative Complications | 33 | 2023 | 15832 | 0.730 |
Why?
|
| Hydrocephalus | 6 | 2013 | 768 | 0.720 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2018 | 58 | 0.690 |
Why?
|
| Ventriculoperitoneal Shunt | 3 | 2011 | 186 | 0.660 |
Why?
|
| Supratentorial Neoplasms | 4 | 2009 | 156 | 0.600 |
Why?
|
| Spondylosis | 4 | 2024 | 85 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2024 | 928 | 0.590 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2006 | 197 | 0.580 |
Why?
|
| Evidence-Based Medicine | 4 | 2012 | 3706 | 0.550 |
Why?
|
| Lumbar Vertebrae | 6 | 2016 | 1885 | 0.550 |
Why?
|
| Societies, Medical | 6 | 2014 | 3968 | 0.510 |
Why?
|
| Hospital Charges | 7 | 2010 | 347 | 0.500 |
Why?
|
| Glioma | 15 | 2019 | 3503 | 0.500 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 1363 | 0.490 |
Why?
|
| Cervical Vertebrae | 5 | 2024 | 979 | 0.490 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2023 | 2059 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2022 | 9419 | 0.460 |
Why?
|
| Radiotherapy, Adjuvant | 13 | 2020 | 1791 | 0.450 |
Why?
|
| Spinal Cord Diseases | 4 | 2024 | 291 | 0.450 |
Why?
|
| Humans | 217 | 2024 | 768166 | 0.440 |
Why?
|
| Hearing Loss | 7 | 2017 | 785 | 0.430 |
Why?
|
| Workload | 3 | 2004 | 849 | 0.430 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2024 | 951 | 0.430 |
Why?
|
| Vascular Surgical Procedures | 5 | 2009 | 1506 | 0.430 |
Why?
|
| Treatment Outcome | 54 | 2024 | 65371 | 0.420 |
Why?
|
| Neurology | 2 | 2012 | 786 | 0.420 |
Why?
|
| Centralized Hospital Services | 4 | 2005 | 15 | 0.420 |
Why?
|
| Length of Stay | 12 | 2012 | 6498 | 0.410 |
Why?
|
| Mutation | 21 | 2024 | 30238 | 0.400 |
Why?
|
| Nimodipine | 3 | 2017 | 56 | 0.400 |
Why?
|
| Publishing | 2 | 2023 | 837 | 0.400 |
Why?
|
| Ventriculostomy | 1 | 2013 | 132 | 0.380 |
Why?
|
| Adult | 109 | 2024 | 223646 | 0.380 |
Why?
|
| Middle Aged | 109 | 2024 | 223492 | 0.380 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2665 | 0.370 |
Why?
|
| Laser Therapy | 2 | 2018 | 1107 | 0.370 |
Why?
|
| Facial Nerve | 4 | 2023 | 277 | 0.370 |
Why?
|
| Lymphoma | 2 | 2024 | 1898 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2018 | 10399 | 0.360 |
Why?
|
| Telomerase | 6 | 2024 | 751 | 0.350 |
Why?
|
| Male | 125 | 2024 | 364719 | 0.350 |
Why?
|
| Aged | 85 | 2024 | 171504 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2830 | 0.340 |
Why?
|
| Embolization, Therapeutic | 3 | 2009 | 1402 | 0.340 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2007 | 640 | 0.330 |
Why?
|
| Congresses as Topic | 1 | 2014 | 812 | 0.320 |
Why?
|
| Female | 125 | 2024 | 397192 | 0.320 |
Why?
|
| Spinal Cord Compression | 2 | 2011 | 234 | 0.320 |
Why?
|
| Clinical Trials as Topic | 9 | 2017 | 8054 | 0.310 |
Why?
|
| Aged, 80 and over | 41 | 2024 | 59629 | 0.310 |
Why?
|
| Disease Progression | 17 | 2024 | 13671 | 0.310 |
Why?
|
| Retrospective Studies | 53 | 2024 | 81762 | 0.310 |
Why?
|
| Thrombolytic Therapy | 2 | 2010 | 2055 | 0.310 |
Why?
|
| Patient Selection | 5 | 2019 | 4260 | 0.310 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2012 | 497 | 0.300 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 640 | 0.300 |
Why?
|
| Cavernous Sinus | 3 | 2006 | 121 | 0.300 |
Why?
|
| United States | 38 | 2023 | 73039 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2013 | 2056 | 0.290 |
Why?
|
| Review Literature as Topic | 2 | 2009 | 297 | 0.290 |
Why?
|
| Spinal Fusion | 5 | 2024 | 1307 | 0.290 |
Why?
|
| Neurofibromin 2 | 3 | 2024 | 271 | 0.290 |
Why?
|
| Hospitals | 6 | 2012 | 3886 | 0.280 |
Why?
|
| Otologic Surgical Procedures | 2 | 2012 | 148 | 0.280 |
Why?
|
| Cranial Nerve Neoplasms | 2 | 2006 | 131 | 0.280 |
Why?
|
| Socioeconomic Factors | 6 | 2023 | 7852 | 0.270 |
Why?
|
| Research Design | 6 | 2018 | 6211 | 0.270 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2009 | 1024 | 0.270 |
Why?
|
| Databases, Factual | 11 | 2018 | 8080 | 0.270 |
Why?
|
| Facial Paralysis | 2 | 2023 | 346 | 0.270 |
Why?
|
| Seizures | 4 | 2016 | 2998 | 0.260 |
Why?
|
| Hospitals, Teaching | 2 | 2012 | 1157 | 0.260 |
Why?
|
| Awards and Prizes | 2 | 2014 | 365 | 0.260 |
Why?
|
| Skull Base Neoplasms | 4 | 2017 | 279 | 0.260 |
Why?
|
| Adolescent | 46 | 2020 | 89169 | 0.250 |
Why?
|
| Meningitis | 1 | 2007 | 219 | 0.250 |
Why?
|
| Combined Modality Therapy | 16 | 2019 | 8542 | 0.250 |
Why?
|
| Hearing Disorders | 2 | 2003 | 126 | 0.240 |
Why?
|
| Stereotaxic Techniques | 2 | 2005 | 553 | 0.230 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2010 | 1165 | 0.230 |
Why?
|
| Surgical Instruments | 3 | 2011 | 381 | 0.230 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3603 | 0.230 |
Why?
|
| Marital Status | 1 | 2005 | 426 | 0.230 |
Why?
|
| Surgical Wound Infection | 6 | 2008 | 1546 | 0.220 |
Why?
|
| Foramen Magnum | 1 | 2024 | 41 | 0.220 |
Why?
|
| Genes, p53 | 3 | 2005 | 714 | 0.220 |
Why?
|
| Quinazolines | 1 | 2010 | 1373 | 0.220 |
Why?
|
| Pseudotumor Cerebri | 1 | 2005 | 107 | 0.220 |
Why?
|
| Healthcare Disparities | 2 | 2010 | 3415 | 0.220 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 829 | 0.220 |
Why?
|
| Glossopharyngeal Nerve Diseases | 1 | 2003 | 9 | 0.220 |
Why?
|
| Protons | 5 | 2023 | 1113 | 0.220 |
Why?
|
| Follow-Up Studies | 28 | 2024 | 39348 | 0.220 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5520 | 0.220 |
Why?
|
| Hemifacial Spasm | 1 | 2003 | 23 | 0.220 |
Why?
|
| Quality of Life | 9 | 2022 | 13490 | 0.210 |
Why?
|
| Paresis | 2 | 2006 | 177 | 0.210 |
Why?
|
| Survival Analysis | 14 | 2019 | 10101 | 0.210 |
Why?
|
| Eligibility Determination | 1 | 2007 | 421 | 0.210 |
Why?
|
| Microsurgery | 4 | 2003 | 800 | 0.210 |
Why?
|
| Sphenoid Bone | 1 | 2003 | 176 | 0.200 |
Why?
|
| Semicircular Canals | 1 | 2004 | 203 | 0.200 |
Why?
|
| Vertigo | 1 | 2004 | 205 | 0.200 |
Why?
|
| Neurilemmoma | 2 | 2010 | 522 | 0.190 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 13676 | 0.190 |
Why?
|
| Seasons | 2 | 2012 | 1524 | 0.190 |
Why?
|
| Aphasia | 1 | 2003 | 193 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2004 | 207 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2024 | 2457 | 0.190 |
Why?
|
| Prognosis | 24 | 2024 | 30010 | 0.190 |
Why?
|
| Brain Ischemia | 3 | 2010 | 3007 | 0.180 |
Why?
|
| Brain Diseases | 2 | 2004 | 1554 | 0.180 |
Why?
|
| Myometrium | 2 | 1998 | 174 | 0.180 |
Why?
|
| Angioplasty | 1 | 2004 | 355 | 0.180 |
Why?
|
| Stroke | 3 | 2012 | 9755 | 0.180 |
Why?
|
| Ataxia | 1 | 2003 | 307 | 0.180 |
Why?
|
| Gene Amplification | 1 | 2005 | 1095 | 0.180 |
Why?
|
| Audiometry, Pure-Tone | 2 | 2012 | 210 | 0.180 |
Why?
|
| Cerebellar Neoplasms | 2 | 2014 | 591 | 0.180 |
Why?
|
| Multivariate Analysis | 13 | 2014 | 12077 | 0.180 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2014 | 263 | 0.180 |
Why?
|
| Tinnitus | 1 | 2023 | 197 | 0.170 |
Why?
|
| Parkinsonian Disorders | 1 | 2023 | 285 | 0.170 |
Why?
|
| Cranial Fossa, Posterior | 3 | 2006 | 134 | 0.170 |
Why?
|
| Cohort Studies | 18 | 2018 | 41754 | 0.170 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2003 | 360 | 0.170 |
Why?
|
| Databases as Topic | 3 | 2009 | 472 | 0.170 |
Why?
|
| Patient Admission | 2 | 2004 | 1365 | 0.170 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2001 | 141 | 0.170 |
Why?
|
| Maternal Mortality | 2 | 2013 | 310 | 0.170 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 1456 | 0.170 |
Why?
|
| Cognition Disorders | 3 | 2019 | 3980 | 0.160 |
Why?
|
| Age Factors | 12 | 2014 | 18412 | 0.160 |
Why?
|
| Medical Staff, Hospital | 1 | 2003 | 603 | 0.160 |
Why?
|
| Parkinson Disease | 2 | 2023 | 2893 | 0.160 |
Why?
|
| Child | 30 | 2020 | 80917 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2021 | 36743 | 0.160 |
Why?
|
| History, 20th Century | 5 | 2014 | 2766 | 0.160 |
Why?
|
| Specialization | 1 | 2004 | 779 | 0.160 |
Why?
|
| Cochlear Nerve | 3 | 2015 | 202 | 0.160 |
Why?
|
| Antimetabolites | 2 | 1996 | 128 | 0.160 |
Why?
|
| Neurologic Examination | 3 | 2017 | 914 | 0.150 |
Why?
|
| Chordoma | 2 | 2014 | 349 | 0.150 |
Why?
|
| Chromosome Aberrations | 3 | 2009 | 1778 | 0.150 |
Why?
|
| Editorial Policies | 1 | 2023 | 458 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2023 | 378 | 0.150 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2009 | 243 | 0.150 |
Why?
|
| Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
| Prospective Studies | 22 | 2024 | 54926 | 0.150 |
Why?
|
| Trephining | 1 | 1997 | 18 | 0.150 |
Why?
|
| Survival Rate | 16 | 2024 | 12840 | 0.150 |
Why?
|
| Education, Medical | 1 | 2010 | 1742 | 0.150 |
Why?
|
| History, 19th Century | 5 | 2009 | 714 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2010 | 4310 | 0.150 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 465 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11878 | 0.140 |
Why?
|
| Guanidines | 1 | 2018 | 194 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2006 | 1502 | 0.140 |
Why?
|
| Electric Stimulation Therapy | 1 | 2003 | 635 | 0.140 |
Why?
|
| International Classification of Diseases | 3 | 2013 | 937 | 0.140 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 1997 | 42 | 0.140 |
Why?
|
| Prostheses and Implants | 2 | 2009 | 1276 | 0.140 |
Why?
|
| Dystrophin | 1 | 2018 | 284 | 0.140 |
Why?
|
| Hearing Tests | 2 | 2017 | 123 | 0.140 |
Why?
|
| Regression Analysis | 7 | 2013 | 6340 | 0.140 |
Why?
|
| Hospitalization | 4 | 2015 | 10840 | 0.140 |
Why?
|
| Brachytherapy | 2 | 2019 | 1220 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2021 | 594 | 0.140 |
Why?
|
| Postoperative Period | 4 | 2020 | 1826 | 0.140 |
Why?
|
| Risk Assessment | 7 | 2020 | 24315 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2010 | 3239 | 0.130 |
Why?
|
| Anticonvulsants | 2 | 2016 | 1923 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 2 | 2024 | 2227 | 0.130 |
Why?
|
| Hypesthesia | 1 | 1997 | 106 | 0.130 |
Why?
|
| Piracetam | 1 | 2016 | 88 | 0.130 |
Why?
|
| Child, Preschool | 17 | 2020 | 42669 | 0.130 |
Why?
|
| Auditory Brain Stem Implants | 1 | 2016 | 33 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2020 | 492 | 0.130 |
Why?
|
| Phenytoin | 1 | 2016 | 189 | 0.130 |
Why?
|
| Deoxyglucose | 1 | 1997 | 333 | 0.130 |
Why?
|
| Hearing | 3 | 2017 | 504 | 0.130 |
Why?
|
| Vision Disorders | 1 | 2003 | 1093 | 0.130 |
Why?
|
| Epilepsy | 1 | 2011 | 3327 | 0.130 |
Why?
|
| Cranial Nerve Injuries | 1 | 2015 | 28 | 0.130 |
Why?
|
| Tic Disorders | 1 | 1997 | 140 | 0.130 |
Why?
|
| Bromodeoxyuridine | 1 | 1996 | 310 | 0.130 |
Why?
|
| Phrenology | 1 | 1995 | 5 | 0.130 |
Why?
|
| Sphenoid Sinus | 3 | 2009 | 101 | 0.130 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2009 | 263 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2007 | 3488 | 0.120 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1998 | 707 | 0.120 |
Why?
|
| Auditory Brain Stem Implantation | 1 | 2015 | 15 | 0.120 |
Why?
|
| Pain, Intractable | 1 | 1996 | 132 | 0.120 |
Why?
|
| Odds Ratio | 6 | 2019 | 9669 | 0.120 |
Why?
|
| Spine | 1 | 2002 | 1140 | 0.120 |
Why?
|
| Young Adult | 18 | 2024 | 60066 | 0.120 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2015 | 53 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6526 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 211 | 0.120 |
Why?
|
| Obesity | 2 | 2007 | 13090 | 0.120 |
Why?
|
| Trigeminal Nerve | 1 | 1996 | 248 | 0.120 |
Why?
|
| Spasm | 1 | 1995 | 131 | 0.120 |
Why?
|
| Hemangioblastoma | 1 | 2014 | 62 | 0.120 |
Why?
|
| Brain Injuries | 2 | 1997 | 2057 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2019 | 793 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 2080 | 0.110 |
Why?
|
| Oximes | 1 | 2015 | 303 | 0.110 |
Why?
|
| Facial Muscles | 1 | 1995 | 159 | 0.110 |
Why?
|
| Streptococcal Infections | 2 | 2010 | 619 | 0.110 |
Why?
|
| Spinal Neoplasms | 2 | 2012 | 715 | 0.110 |
Why?
|
| History, 21st Century | 2 | 2014 | 1573 | 0.110 |
Why?
|
| Valine | 1 | 2015 | 410 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 1375 | 0.110 |
Why?
|
| Skull Base | 1 | 2016 | 294 | 0.110 |
Why?
|
| Fluorine Radioisotopes | 1 | 1997 | 425 | 0.110 |
Why?
|
| Bacterial Infections | 2 | 2009 | 1397 | 0.110 |
Why?
|
| Premedication | 1 | 1994 | 246 | 0.110 |
Why?
|
| Cause of Death | 2 | 2004 | 3721 | 0.110 |
Why?
|
| Anniversaries and Special Events | 1 | 2014 | 97 | 0.110 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2015 | 154 | 0.110 |
Why?
|
| Disease Management | 2 | 2016 | 2536 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2018 | 2675 | 0.110 |
Why?
|
| Conflict of Interest | 1 | 2018 | 556 | 0.110 |
Why?
|
| Facial Nerve Diseases | 1 | 2013 | 49 | 0.110 |
Why?
|
| Hospital Departments | 1 | 1993 | 135 | 0.110 |
Why?
|
| Face | 3 | 2023 | 1029 | 0.110 |
Why?
|
| Gene Targeting | 1 | 2016 | 841 | 0.110 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2013 | 66 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 905 | 0.110 |
Why?
|
| Time Factors | 11 | 2016 | 40218 | 0.110 |
Why?
|
| Otolaryngology | 1 | 2020 | 699 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 304 | 0.110 |
Why?
|
| Pyrimidinones | 1 | 2015 | 386 | 0.100 |
Why?
|
| Internship and Residency | 2 | 2014 | 5953 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 2024 | 44 | 0.100 |
Why?
|
| Logistic Models | 6 | 2015 | 13290 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 687 | 0.100 |
Why?
|
| Infant | 12 | 2020 | 36535 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 810 | 0.100 |
Why?
|
| Reoperation | 7 | 2016 | 4329 | 0.100 |
Why?
|
| Internet | 3 | 2010 | 3110 | 0.100 |
Why?
|
| Risk Factors | 14 | 2024 | 74944 | 0.100 |
Why?
|
| Drug Industry | 1 | 2018 | 791 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 2655 | 0.100 |
Why?
|
| Cranial Nerves | 2 | 2021 | 97 | 0.100 |
Why?
|
| Carotid Artery, Internal | 1 | 1994 | 440 | 0.100 |
Why?
|
| Deafness | 1 | 2016 | 460 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2008 | 614 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2013 | 3514 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 5367 | 0.100 |
Why?
|
| Radiotherapy Dosage | 7 | 2009 | 2916 | 0.090 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 306 | 0.090 |
Why?
|
| Biopsy, Needle | 4 | 2005 | 1622 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 1997 | 683 | 0.090 |
Why?
|
| Arteriovenous Fistula | 1 | 1994 | 320 | 0.090 |
Why?
|
| Neoplasms | 3 | 2015 | 22371 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 5703 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2013 | 590 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 990 | 0.090 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 12543 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 1996 | 1259 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 2810 | 0.090 |
Why?
|
| Linear Models | 2 | 2011 | 5884 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 1397 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 620 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1015 | 0.090 |
Why?
|
| Cauda Equina | 1 | 2010 | 45 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 5 | 2024 | 5797 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 958 | 0.090 |
Why?
|
| Pyridones | 1 | 2015 | 819 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 2298 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2019 | 2923 | 0.090 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 2973 | 0.080 |
Why?
|
| Fusobacterium Infections | 1 | 2010 | 54 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 260 | 0.080 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 329 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2015 | 1191 | 0.080 |
Why?
|
| Neurofibromatoses | 1 | 2013 | 303 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 2024 | 1744 | 0.080 |
Why?
|
| Necrosis | 3 | 2005 | 1616 | 0.080 |
Why?
|
| Cerebral Revascularization | 1 | 2012 | 260 | 0.080 |
Why?
|
| Recurrence | 7 | 2017 | 8509 | 0.080 |
Why?
|
| Imidazoles | 1 | 2015 | 1169 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 879 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2010 | 133 | 0.080 |
Why?
|
| Morbidity | 3 | 2003 | 1755 | 0.080 |
Why?
|
| Inpatients | 2 | 2011 | 2566 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2862 | 0.080 |
Why?
|
| Brain Abscess | 1 | 2010 | 123 | 0.080 |
Why?
|
| Ischemic Attack, Transient | 2 | 1996 | 877 | 0.080 |
Why?
|
| Hospitals, General | 1 | 1993 | 809 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 2709 | 0.080 |
Why?
|
| Patient Discharge | 3 | 2010 | 3479 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2014 | 1906 | 0.080 |
Why?
|
| Cochlea | 1 | 2015 | 848 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 592 | 0.080 |
Why?
|
| Frontal Lobe | 1 | 1995 | 1426 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 275 | 0.080 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 6847 | 0.080 |
Why?
|
| Skull | 2 | 2008 | 820 | 0.080 |
Why?
|
| Pneumocephalus | 1 | 2008 | 46 | 0.070 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2010 | 141 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2004 | 4858 | 0.070 |
Why?
|
| Neurofibromatosis 1 | 1 | 2013 | 561 | 0.070 |
Why?
|
| Sex Factors | 5 | 2020 | 10632 | 0.070 |
Why?
|
| Encephalocele | 1 | 2009 | 135 | 0.070 |
Why?
|
| Obstetric Labor, Premature | 3 | 2015 | 268 | 0.070 |
Why?
|
| Tracheotomy | 1 | 2008 | 174 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4860 | 0.070 |
Why?
|
| Computers, Handheld | 1 | 2009 | 211 | 0.070 |
Why?
|
| Cognition | 2 | 2016 | 7073 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2885 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 396 | 0.070 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 9615 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 663 | 0.070 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 1042 | 0.070 |
Why?
|
| Ear, Inner | 2 | 2009 | 426 | 0.070 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 2972 | 0.070 |
Why?
|
| Supine Position | 1 | 2007 | 208 | 0.070 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 15454 | 0.070 |
Why?
|
| Safety Management | 1 | 2012 | 765 | 0.070 |
Why?
|
| Bibliography of Medicine | 1 | 2005 | 2 | 0.070 |
Why?
|
| Fasciitis | 1 | 1987 | 66 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 3728 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 2360 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 879 | 0.060 |
Why?
|
| Statistics as Topic | 3 | 2003 | 2357 | 0.060 |
Why?
|
| Prone Position | 1 | 2007 | 203 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2846 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2005 | 2359 | 0.060 |
Why?
|
| Speech Perception | 1 | 2010 | 510 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 710 | 0.060 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 128 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 1135 | 0.060 |
Why?
|
| Facial Pain | 1 | 2006 | 121 | 0.060 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2008 | 325 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2008 | 552 | 0.060 |
Why?
|
| Astrocytoma | 3 | 2002 | 774 | 0.060 |
Why?
|
| Brain Stem | 2 | 2016 | 859 | 0.060 |
Why?
|
| Foundations | 1 | 2005 | 96 | 0.060 |
Why?
|
| Genomics | 2 | 2020 | 5926 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2006 | 286 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2020 | 26422 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2024 | 4120 | 0.060 |
Why?
|
| Mathematical Computing | 1 | 2004 | 142 | 0.060 |
Why?
|
| Physicians | 3 | 2009 | 4598 | 0.060 |
Why?
|
| Cisterna Magna | 1 | 2004 | 39 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2019 | 3857 | 0.060 |
Why?
|
| Remission Induction | 2 | 2023 | 2410 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2010 | 783 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2017 | 630 | 0.060 |
Why?
|
| Cranial Fossa, Middle | 1 | 2004 | 29 | 0.060 |
Why?
|
| Prevalence | 3 | 2024 | 15869 | 0.060 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.060 |
Why?
|
| RNA Polymerase III | 1 | 2024 | 59 | 0.060 |
Why?
|
| Genotype | 1 | 2018 | 13045 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2020 | 12168 | 0.060 |
Why?
|
| Gyrus Cinguli | 1 | 2010 | 1135 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 1997 | 4937 | 0.050 |
Why?
|
| Alkynes | 1 | 2024 | 326 | 0.050 |
Why?
|
| Health Facility Size | 1 | 2003 | 59 | 0.050 |
Why?
|
| Adenoma | 3 | 2006 | 2159 | 0.050 |
Why?
|
| Carmustine | 1 | 2003 | 137 | 0.050 |
Why?
|
| Nevirapine | 1 | 2024 | 273 | 0.050 |
Why?
|
| Ghana | 1 | 2024 | 333 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7454 | 0.050 |
Why?
|
| Brain | 9 | 2022 | 27360 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1932 | 0.050 |
Why?
|
| Radiography | 3 | 2021 | 6983 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 381 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2024 | 436 | 0.050 |
Why?
|
| Peer Review | 1 | 2005 | 218 | 0.050 |
Why?
|
| Diagnosis-Related Groups | 1 | 2004 | 445 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
| Publications | 1 | 2005 | 195 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2024 | 320 | 0.050 |
Why?
|
| Phototherapy | 1 | 2006 | 368 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2014 | 2346 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2003 | 202 | 0.050 |
Why?
|
| Emergencies | 1 | 2009 | 1221 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 183 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2019 | 2661 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1997 | 1062 | 0.050 |
Why?
|
| Publication Bias | 1 | 2002 | 158 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 876 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 744 | 0.050 |
Why?
|
| Hospital Information Systems | 1 | 2004 | 395 | 0.050 |
Why?
|
| Otitis Media | 1 | 2004 | 288 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1245 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3463 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2007 | 848 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2001 | 6229 | 0.050 |
Why?
|
| Karnofsky Performance Status | 2 | 2003 | 162 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2024 | 507 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2001 | 325 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2005 | 696 | 0.040 |
Why?
|
| Cushing Syndrome | 2 | 1999 | 241 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 13586 | 0.040 |
Why?
|
| Nerve Compression Syndromes | 2 | 2006 | 160 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 637 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2004 | 1092 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 1359 | 0.040 |
Why?
|
| Cesarean Section | 3 | 2015 | 1425 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 2954 | 0.040 |
Why?
|
| Cesium Radioisotopes | 1 | 2019 | 38 | 0.040 |
Why?
|
| Steroids | 1 | 2005 | 938 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 2420 | 0.040 |
Why?
|
| Thromboplastin | 1 | 2001 | 289 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 3533 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 26379 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 2517 | 0.040 |
Why?
|
| Incidence | 4 | 2008 | 21538 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2011 | 2517 | 0.040 |
Why?
|
| World Health Organization | 2 | 2015 | 1329 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2007 | 13053 | 0.040 |
Why?
|
| Prolactin | 1 | 2001 | 627 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 1997 | 574 | 0.040 |
Why?
|
| Fever | 1 | 2007 | 1614 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2008 | 2815 | 0.040 |
Why?
|
| Endoscopy | 2 | 1999 | 1854 | 0.040 |
Why?
|
| Sex Chromatin | 1 | 2018 | 19 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2009 | 2589 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2009 | 1516 | 0.040 |
Why?
|
| Acromegaly | 2 | 1999 | 317 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 3620 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5432 | 0.040 |
Why?
|
| Endometrium | 1 | 2001 | 406 | 0.040 |
Why?
|
| Vestibular Nerve | 1 | 1998 | 101 | 0.040 |
Why?
|
| Fetal Growth Retardation | 2 | 2013 | 592 | 0.040 |
Why?
|
| Medicaid | 1 | 2011 | 2840 | 0.040 |
Why?
|
| Drug Delivery Systems | 2 | 2020 | 2232 | 0.040 |
Why?
|
| Decision Making | 1 | 2012 | 3953 | 0.040 |
Why?
|
| Anaplasia | 1 | 1997 | 16 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 5536 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3929 | 0.040 |
Why?
|
| Connexin 43 | 1 | 1998 | 202 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 3671 | 0.040 |
Why?
|
| Histone Demethylases | 1 | 2020 | 328 | 0.040 |
Why?
|
| HIV Infections | 1 | 2024 | 17569 | 0.040 |
Why?
|
| Head | 1 | 2023 | 926 | 0.040 |
Why?
|
| Data Collection | 1 | 2007 | 3327 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2003 | 957 | 0.040 |
Why?
|
| Health Resources | 1 | 2023 | 950 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 162 | 0.040 |
Why?
|
| Canada | 1 | 2022 | 2130 | 0.030 |
Why?
|
| Meniere Disease | 1 | 1998 | 164 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1323 | 0.030 |
Why?
|
| Acute Disease | 2 | 2004 | 7243 | 0.030 |
Why?
|
| Thalamus | 1 | 2003 | 1047 | 0.030 |
Why?
|
| Silver | 1 | 1997 | 119 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 20227 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 6082 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 687 | 0.030 |
Why?
|
| Visual Fields | 1 | 2003 | 1065 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 11095 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 416 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 9263 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 788 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2019 | 1034 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 1997 | 274 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 1994 | 7477 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 16045 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2001 | 1336 | 0.030 |
Why?
|
| Basilar Artery | 1 | 1996 | 207 | 0.030 |
Why?
|
| Vertebral Artery | 1 | 1996 | 185 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 329 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1996 | 133 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 1997 | 316 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1995 | 256 | 0.030 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3948 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2005 | 2596 | 0.030 |
Why?
|
| Ethmoid Sinus | 1 | 1994 | 58 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1995 | 322 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 154 | 0.030 |
Why?
|
| Cell Division | 3 | 2001 | 4473 | 0.030 |
Why?
|
| Lectins | 2 | 2007 | 490 | 0.030 |
Why?
|
| Meningeal Arteries | 1 | 1994 | 66 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2017 | 326 | 0.030 |
Why?
|
| Adipokines | 2 | 2007 | 309 | 0.030 |
Why?
|
| Ophthalmic Artery | 1 | 1994 | 57 | 0.030 |
Why?
|
| Uterine Diseases | 1 | 1995 | 108 | 0.030 |
Why?
|
| Uterus | 1 | 1998 | 663 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2005 | 1465 | 0.030 |
Why?
|
| Pre-Eclampsia | 2 | 2015 | 1255 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 513 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 246 | 0.030 |
Why?
|
| Gap Junctions | 1 | 1995 | 230 | 0.030 |
Why?
|
| Skull Neoplasms | 1 | 1995 | 173 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2020 | 790 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2332 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1997 | 2000 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 4058 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1998 | 910 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2014 | 323 | 0.030 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2015 | 256 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 735 | 0.030 |
Why?
|
| Bone Wires | 1 | 1994 | 125 | 0.030 |
Why?
|
| Prodrugs | 1 | 1995 | 274 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1998 | 966 | 0.030 |
Why?
|
| Gallbladder Neoplasms | 1 | 1995 | 190 | 0.030 |
Why?
|
| Arteries | 2 | 1996 | 1127 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 1996 | 855 | 0.030 |
Why?
|
| Vestibulocochlear Nerve | 1 | 2013 | 115 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2627 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 2599 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2003 | 2981 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 3556 | 0.030 |
Why?
|
| Patient Participation | 1 | 2002 | 1447 | 0.030 |
Why?
|
| Forecasting | 1 | 2022 | 2945 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2001 | 3160 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2021 | 1811 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2007 | 3288 | 0.030 |
Why?
|
| Capsicum | 1 | 1992 | 7 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 3780 | 0.030 |
Why?
|
| Gadolinium | 1 | 1997 | 964 | 0.030 |
Why?
|
| Indium Radioisotopes | 1 | 1992 | 116 | 0.020 |
Why?
|
| Scalp | 1 | 1995 | 391 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2004 | 11244 | 0.020 |
Why?
|
| Simplexvirus | 1 | 1995 | 805 | 0.020 |
Why?
|
| Pharynx | 1 | 1994 | 436 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1994 | 585 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 736 | 0.020 |
Why?
|
| Paranasal Sinuses | 2 | 2009 | 267 | 0.020 |
Why?
|
| beta Catenin | 1 | 2016 | 1047 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1886 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1992 | 138 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 1992 | 167 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3436 | 0.020 |
Why?
|
| Personality | 1 | 1995 | 559 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2008 | 20760 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 14729 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 1996 | 969 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2004 | 9384 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2010 | 13014 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 542 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 22291 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 1208 | 0.020 |
Why?
|
| Bone Plates | 1 | 1994 | 468 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2622 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 2420 | 0.020 |
Why?
|
| Streptococcus anginosus | 1 | 2010 | 25 | 0.020 |
Why?
|
| Bone Screws | 1 | 1994 | 534 | 0.020 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2009 | 13 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3611 | 0.020 |
Why?
|
| Boston | 2 | 2012 | 9374 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 14783 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1480 | 0.020 |
Why?
|
| Palliative Care | 1 | 2005 | 3643 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1998 | 1536 | 0.020 |
Why?
|
| Probability | 1 | 1995 | 2479 | 0.020 |
Why?
|
| Neuropilin-2 | 1 | 2009 | 55 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 1992 | 314 | 0.020 |
Why?
|
| Epistaxis | 1 | 2010 | 117 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 2043 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 6395 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1996 | 1429 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2004 | 5107 | 0.020 |
Why?
|
| Cerebellum | 1 | 1996 | 1522 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2009 | 91 | 0.020 |
Why?
|
| Glycoproteins | 2 | 2007 | 2202 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2434 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 1992 | 602 | 0.020 |
Why?
|
| Fusobacterium nucleatum | 1 | 2010 | 176 | 0.020 |
Why?
|
| Oropharynx | 1 | 2009 | 139 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2016 | 1835 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2016 | 5315 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1885 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2732 | 0.020 |
Why?
|
| Osteotomy | 1 | 1994 | 838 | 0.020 |
Why?
|
| Sclerosis | 1 | 1989 | 211 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2024 | 4573 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 1505 | 0.020 |
Why?
|
| Heart Atria | 1 | 1994 | 1361 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2008 | 48 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 2430 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1997 | 2055 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1992 | 520 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2907 | 0.020 |
Why?
|
| Risk | 2 | 1996 | 9613 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 640 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1994 | 1131 | 0.020 |
Why?
|
| Pregnancy | 3 | 2015 | 30256 | 0.020 |
Why?
|
| Ependymoma | 1 | 2010 | 328 | 0.020 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2013 | 529 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1995 | 1061 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 412 | 0.020 |
Why?
|
| Endometriosis | 1 | 1995 | 873 | 0.020 |
Why?
|
| Gangrene | 1 | 1987 | 92 | 0.020 |
Why?
|
| Age of Onset | 2 | 2006 | 3347 | 0.020 |
Why?
|
| Rhizotomy | 1 | 2006 | 30 | 0.020 |
Why?
|
| Neutrons | 1 | 2006 | 78 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 547 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 103 | 0.020 |
Why?
|
| Selection Bias | 1 | 2008 | 360 | 0.020 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2006 | 122 | 0.020 |
Why?
|
| Pain Measurement | 1 | 1996 | 3583 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 2381 | 0.020 |
Why?
|
| Cell Survival | 1 | 1995 | 5777 | 0.020 |
Why?
|
| Thromboembolism | 1 | 1992 | 1004 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 343 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2003 | 4818 | 0.020 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 15 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 1219 | 0.020 |
Why?
|
| Cadmium Compounds | 1 | 1984 | 15 | 0.020 |
Why?
|
| Heparin | 1 | 1992 | 1636 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 954 | 0.010 |
Why?
|
| Confusion | 1 | 2006 | 278 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 6316 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2006 | 488 | 0.010 |
Why?
|
| Contrast Media | 1 | 1997 | 5330 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 2010 | 758 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3474 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2006 | 290 | 0.010 |
Why?
|
| Injections, Subcutaneous | 2 | 1998 | 687 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 280 | 0.010 |
Why?
|
| Sarcoma | 1 | 1995 | 1806 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 4786 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2017 | 8741 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2018 | 12800 | 0.010 |
Why?
|
| Carbon | 1 | 2006 | 673 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 10760 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 160 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1996 | 6283 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2631 | 0.010 |
Why?
|
| Preoperative Care | 2 | 2003 | 2258 | 0.010 |
Why?
|
| Biopsy | 2 | 2005 | 6793 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1444 | 0.010 |
Why?
|
| Microcirculation | 1 | 2006 | 1281 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 17140 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10474 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 1946 | 0.010 |
Why?
|
| Decidua | 1 | 2001 | 82 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 5100 | 0.010 |
Why?
|
| Colposcopy | 1 | 2001 | 151 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 3044 | 0.010 |
Why?
|
| Absorbable Implants | 1 | 2003 | 337 | 0.010 |
Why?
|
| Choline | 1 | 2002 | 522 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 14164 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 899 | 0.010 |
Why?
|
| Registries | 2 | 2010 | 8375 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8748 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5341 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6611 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7140 | 0.010 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 1999 | 16 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2006 | 1273 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2001 | 343 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2003 | 770 | 0.010 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1999 | 29 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2004 | 596 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 1611 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2006 | 2264 | 0.010 |
Why?
|
| Hypophysectomy | 1 | 1999 | 114 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 15948 | 0.010 |
Why?
|
| Software | 1 | 2013 | 4478 | 0.010 |
Why?
|
| Brain Edema | 1 | 2003 | 601 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1999 | 285 | 0.010 |
Why?
|
| Animals | 5 | 2018 | 169246 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2015 | 23645 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7453 | 0.010 |
Why?
|
| Prolactinoma | 1 | 1999 | 114 | 0.010 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2001 | 392 | 0.010 |
Why?
|
| Disabled Persons | 2 | 1998 | 1210 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2006 | 2062 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 2300 | 0.010 |
Why?
|
| Virus Replication | 1 | 2004 | 2458 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 2725 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2001 | 863 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 9015 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12795 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 4912 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 1630 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1995 | 5863 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1995 | 286 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1998 | 1151 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 8317 | 0.010 |
Why?
|
| Cell Polarity | 1 | 1998 | 639 | 0.010 |
Why?
|
| Menorrhagia | 1 | 1995 | 59 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 3402 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1992 | 4916 | 0.010 |
Why?
|
| Temporal Bone | 1 | 1999 | 683 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1995 | 64 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 1702 | 0.010 |
Why?
|
| Bile | 1 | 1995 | 299 | 0.010 |
Why?
|
| Decision Trees | 1 | 1996 | 508 | 0.010 |
Why?
|
| Mice | 2 | 2018 | 82029 | 0.010 |
Why?
|
| Dysmenorrhea | 1 | 1995 | 107 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 9538 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 313 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1996 | 498 | 0.010 |
Why?
|
| Facial Bones | 1 | 1994 | 209 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 1995 | 358 | 0.010 |
Why?
|
| Azoxymethane | 1 | 1992 | 32 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2001 | 11669 | 0.010 |
Why?
|
| Markov Chains | 1 | 1996 | 979 | 0.010 |
Why?
|
| Cephalometry | 1 | 1994 | 380 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2001 | 2857 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1992 | 289 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1995 | 452 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1999 | 1841 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1996 | 1264 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 2087 | 0.010 |
Why?
|
| Bandages | 1 | 1992 | 272 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 4030 | 0.010 |
Why?
|
| Kidney | 1 | 1984 | 7064 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15662 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1996 | 1248 | 0.000 |
Why?
|
| Tomography, Emission-Computed | 1 | 1992 | 1126 | 0.000 |
Why?
|
| Medicare | 1 | 2007 | 6809 | 0.000 |
Why?
|
| Gene Expression | 1 | 2001 | 7598 | 0.000 |
Why?
|
| Cell Communication | 1 | 1995 | 1660 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 6514 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1994 | 2678 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 6124 | 0.000 |
Why?
|
| Phenotype | 1 | 2006 | 16726 | 0.000 |
Why?
|
| Rats | 2 | 1995 | 23760 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1995 | 2932 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1994 | 2363 | 0.000 |
Why?
|
| Lung | 1 | 2005 | 10099 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5804 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2001 | 19015 | 0.000 |
Why?
|
| Tellurium | 1 | 1984 | 23 | 0.000 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1984 | 67 | 0.000 |
Why?
|
| Pentetic Acid | 1 | 1984 | 209 | 0.000 |
Why?
|
| Technetium | 1 | 1984 | 328 | 0.000 |
Why?
|
| Cadmium | 1 | 1984 | 217 | 0.000 |
Why?
|
| RNA | 1 | 1992 | 2720 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1995 | 6004 | 0.000 |
Why?
|
| Radiometry | 1 | 1984 | 818 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 7214 | 0.000 |
Why?
|
| Models, Biological | 1 | 1994 | 9495 | 0.000 |
Why?
|
| Proteins | 1 | 1992 | 6009 | 0.000 |
Why?
|